1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Aclarion, Inc.

Aclarion, Inc.

ACONW
Aclarion, Inc.US flagNASDAQ Capital Market
0.02
USD
+0.00
- -
11,732.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-14,923.98
-9,204.67
-4,899.22
-9,202.51
-6,467.99
-12,057.23
-9,312.55
-10,975.1
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-5
-5
-7
-5
-7
-7
-8
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-14,943.15
-9,527.35
-8,210.53
-11,694.45
-6,513.41
-15,293.78
-9,551.87
-10,336.12
Working Capital
-3
-8
-7
1
-2
- -
12
18
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-2
-7
-6
2
-1
1
13
20
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
2
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
12
12
19
Cash, Cash Equivalents & STI
11
12
19
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
139.84%
1,223.13%
Free Cash Flow
- -
36.37%
35.9%
Net Income, GAAP
- -
12.98%
3.44%
Sales/Revenue/Turnover
- -
15.04%
65.62%
Total Cash Common Dividend
- -
- -
-88.8%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Brent Ness
Full Time Employees
11
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
951 Mariners Island Boulevard Broomfield CA United States of America 94404
IPO Date
Apr 22, 2022
CIK
0001635077
Website
aclarion.com
Similar Companies
Vynleads, Inc. (VYND)
Intelicare Holdings Limited (ICR.AX)
ETAO International Co., Ltd. (ETAO)
Alkuri Global Acquisition Corp. (KURIU)
GE HealthCare Technologies Inc. (GEHC)
Optomed Oyj (OPTOMED.HE)
Business
Aclarion, Inc. Aclarion, Inc. (NASDAQ: ACONW) operates as a healthcare technology company that leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers, including augmented-intelligence algorithms, to deliver noninvasive SaaS platforms optimizing clinical treatments for chronic low back and neck pain; its primary product, NOCISCAN, analyzes the chemical composition of intervertebral discs to distinguish painful (NOCI+) from nonpainful (NOCI-) discs, complemented by NOCISCAN MRS Exam Protocol for extended MRI sequences, AMBRA Healthcare for imaging data transfer, and NOCIWEB for web-based interfaces; the company targets physicians and surgeons addressing the $134.5 billion U.S. low back pain market, with initial focus on improving surgical outcomes for discogenic pain through evidence-based, personalized treatment plans that avoid invasive discography. Founded in 2008 and headquartered in Broomfield, Colorado, Aclarion conducts operations principally in the United States while pursuing international expansion. Recent developments include the appointment of Dan Isherwood as UK Commercial Director in November 2025 to drive European market adoption, winning the "Rising Star" award at the 2025 Digital Health Hub Foundation Awards in October, expansion of NOCISCAN sites with RadNet affiliates in New York and New Jersey, securing nearly $20 million in funding for the pivotal CLARITY clinical trial (first patient enrolled June 2025, additional sites like University of Miami in September), appointment of Greg Gould as CFO in September 2025, and Nasdaq compliance regained in March 2025 following stockholder approval.